These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Management of myelodysplastic syndromes: 2008 update. Scott BL; Estey E Oncology (Williston Park); 2008 Nov; 22(12):1344-52. PubMed ID: 19086598 [TBL] [Abstract][Full Text] [Related]
6. Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society. Meers S; Breems D; Bries G; Delforge M; Graux C; Ravoet C; Selleslag D; Noens L; Acta Clin Belg; 2013; 68(4):253-62. PubMed ID: 24455794 [TBL] [Abstract][Full Text] [Related]
7. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. Ma X; Steensma DP; Scott BL; Kiselev P; Sugrue MM; Swern AS BMJ Open; 2018 Jul; 8(7):e019955. PubMed ID: 30037860 [TBL] [Abstract][Full Text] [Related]
8. [The role of iron metabolism in myelodysplastic syndromes]. Finelli C; Clissa C; Stanzani M Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455 [TBL] [Abstract][Full Text] [Related]
9. Does early diagnosis and treatment of myelodysplastic syndromes make a difference? Steensma DP Best Pract Res Clin Haematol; 2019 Dec; 32(4):101099. PubMed ID: 31779983 [TBL] [Abstract][Full Text] [Related]
10. Therapy for lower-risk MDS. Carraway HE; Saygin C Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714 [TBL] [Abstract][Full Text] [Related]
11. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. Greenberg PL; Cosler LE; Ferro SA; Lyman GH J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in the management of myelodysplastic syndromes. Hamblin T Hematol Oncol; 1993; 11 Suppl 1():27-31. PubMed ID: 8486338 [No Abstract] [Full Text] [Related]
13. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Gattermann N Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200 [TBL] [Abstract][Full Text] [Related]
14. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? Leitch HA; Vickars LM Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252 [TBL] [Abstract][Full Text] [Related]
15. Targeting ineffective hematopoiesis in myelodysplastic syndromes. Patnaik MM; Santini V Am J Hematol; 2022 Feb; 97(2):171-173. PubMed ID: 34800318 [No Abstract] [Full Text] [Related]
16. Myelodysplastic syndromes: a challenging disease for patients and physicians. Somani N J Assoc Physicians India; 2012 Feb; 60():107-8, 113. PubMed ID: 22715557 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia. Tang Y; Zhang X; Han S; Chu T; Qi J; Wang H; Tang X; Qiu H; Fu C; Ruan C; Wu D; Han Y Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):217S-222S. PubMed ID: 30296835 [TBL] [Abstract][Full Text] [Related]
18. How I treat patients with myelodysplastic syndromes. Stone RM Blood; 2009 Jun; 113(25):6296-303. PubMed ID: 19383969 [No Abstract] [Full Text] [Related]
19. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. Leitch HA; Gattermann N Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649 [TBL] [Abstract][Full Text] [Related]
20. How to manage lower-risk myelodysplastic syndromes. Sekeres MA Leukemia; 2012 Mar; 26(3):390-4. PubMed ID: 21904382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]